Literature DB >> 21105122

Bladder cancer: current management and opportunities for a personalized approach.

Matthew D Galsky1, Simon J Hall.   

Abstract

Urothelial carcinoma of the bladder exists as a spectrum of clinical states ranging from non-muscle-invasive to muscle-invasive to advanced/metastatic disease. Each clinical state is associated with a unique tumor biology, prognosis, and approach to treatment. The field of personalized medicine offers the promise to individualize therapeutic decisions in each clinical state with the goal of preventing or delaying progression to more advanced disease states while optimizing quality of life. This review will discuss bladder cancer as a paradigm for the development of personalized cancer medicine, focusing on recent efforts, current challenges, and future opportunities.
© 2010 Mount Sinai School of Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105122     DOI: 10.1002/msj.20224

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  6 in total

1.  The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer.

Authors:  Casey DeDeugd; Makito Miyake; Diego Aguilar Palacios; Charles J Rosser
Journal:  J Racial Ethn Health Disparities       Date:  2014-09-11

Review 2.  Biomarkers for bladder cancer management: present and future.

Authors:  Fei Ye; Li Wang; Mireia Castillo-Martin; Russell McBride; Matthew D Galsky; Jun Zhu; Paolo Boffetta; David Y Zhang; Carlos Cordon-Cardo
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

3.  Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report.

Authors:  Qi Jiang; Mi-Xue Xie; Xiao-Chen Zhang
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

4.  Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index.

Authors:  Sally E Jensen; Jennifer L Beaumont; Paul B Jacobsen; Amy Abernethy; Karen L Syrjala; David Cella
Journal:  J Support Oncol       Date:  2013-06

Review 5.  Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.

Authors:  Dong Chen; Yunlin Ye; Shengjie Guo; Kao Yao
Journal:  Front Mol Biosci       Date:  2021-12-23

6.  Inhibiting invasion into human bladder carcinoma 5637 cells with diallyl trisulfide by inhibiting matrix metalloproteinase activities and tightening tight junctions.

Authors:  Dong Yeok Shin; Hee-Jae Cha; Gi-Young Kim; Wun-Jae Kim; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2013-10-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.